Abstract Organic anion transporter polypeptides (OATPs, SLCOs) are involved in the uptake of conjugates steroid hormones such as estrone-3-sulfate. It has been suggested that the expression of OATPs in breast tissues could impact breast carcinogenesis and tumor pathology. The nuclear receptor pregnane X receptor (PXR) is involved in the regulation of SLCO1A2 expression. We investigated 31 variants located in PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 for an association with breast cancer risk and/ or histo-pathological tumor characteristics. Polymorphisms were selected on the basis of a known or potential functional consequence and an allele frequency[2%. Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the GENICA population-based breast cancer case-control collection comprising 1,021 cases and 1,015 age-matched controls. Statistical analysis was performed by SAS, and all tests were two-sided. None of the 31 analyzed transporter and PXR polymorphisms showed an association with breast cancer risk or tumor characteristics. Our data suggest that among the many known transporters common variations of PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 do not contribute to breast carcinogenesis.
Introduction
The mammary gland is an estrogen target tissue, and plasma levels of estradiol have been linked with breast cancer risk [1] . The metabolite estrone-3-sulfate is considered one of the major precursors of active estrogen in postmenopausal women [2] . Estrone-3-sulfate levels are significantly higher in malignant tissue, resulting in increased levels of 17beta-estradiol [3] . Owing to the hydrophilic nature of this compound, it is likely that an uptake transporter is needed to facilitate the transmembrane entry into tissue such as breast [4] . Recently, the interplay between the nuclear receptor pregnane X receptor (PXR) and the organic anion transporter polypeptide 1A2 (OATP1A2, gene symbol SCLO1A2) has been reported to enhance estrogen effects in breast cancer [5] . The induction of OATP1A2 by the PXR activator rifampin was associated with increased uptake of estrone-3-sulfate, an effect that could be abrogated by small interfering RNA targeting the PXR. The identification of a PXR response element in the SCLO1A2 gene followed by PXR-SCLO1A2 chromatin immunopreciptation with anti PXR, and the reversal of the effect by a potent PXR antagonist substantiated the cooperation between PXR and OATP1A2 [5] . mRNA and protein expression in breast cancer revealed closely correlated high PXR and OATP1A2 levels and suggested that PXR, and its target gene OATP1A2 are histo-pathological markers of dedifferentiation and progression [6] .
The organic anion transporter polypeptides (OATPs encoded by the SLCOs genes) belong to the superfamily of solute carriers [7] [8] [9] . They are expressed in various tissues including liver, kidney, brain, testis as well as breast and mediate the cellular uptake of a broad range of endogenous substrates (e.g., bile acids, thyroide hormones, conjugated steroids including estradiol-17beta-glucuronide, and estrone-3-sulfate) and drugs (e.g., antibiotics, nonsteroidal anti-inflammatory drugs, anti-cancer drug methotrexate) [10] . A number of naturally occurring sequence variants have been identified in OATPs [11, 12] and PXR [13, 14] several of which are relatively common. In the case of OATP1B1, a hepatic estrone-3-sulfate uptake transporter, the genetic variations (e.g., 521 T[C, rs4149056) have been linked with decreased transport activity for an irinotecan derivative SN-38, pravastatin, estrone-3-sulfate and estradiol-17beta-glucuronide [15] [16] [17] . Since this OATP variant may alter the pharmacokinetics of drugs thereby contributing to the inter-individual variability of drug response and/or the development of side effects (e.g., statin-related myopathy), it is plausible to also question a putative role of uptake transporters for breast cancer risk [16, 18, 19] . Of note, estrone-3-sulfate is a substrate for a number of OTAPs including OATP1A2, OATP1B1, OATP1B3 as well as OATP2B1 and for all of these transporters functional relevant genetic variants have been reported [10, [20] [21] [22] [23] . This notion is supported by recent findings from a whole genome scan and association study conducted with more than 37,000 cases and 40,000 controls that revealed the sodium bicarbonate co-transporter SLC4A7 variant rs4973768 to be associated with increased breast cancer risk and tumor estrogen receptor status [24] . Given the biological plausibility and examples of transporter variants involved in health and disease we investigated whether variants at SLCOs as well as the xenobiotic and steroid hormone sensoring PXR may impact breast cancer risk and/or histopathological tumor characteristics. We explored this possibility for 23 SCLO polymorphisms (six at SLCO1A2, six at SLCO1B1, three at SLCO1B3, seven at SLCO2B1) and eight PXR polymorphisms for which functional consequences are known or suggested. Association studies have been performed with the population-based GENICA breast cancer case-control collection (1,021 cases and 1,015 controls) from Germany. None of the polymorphisms showed an association neither with breast cancer risk nor with histopathological tumor characteristics.
Materials and methods

Study population
The GENICA study participants of the population-based breast cancer case-control study from the Greater Bonn Region, Germany, were recruited between August, 2000 and September, 2004 as described previously [25, 26] . In brief, there are 1,143 incident breast cancer cases and 1,155 population controls matched in 5-year classes. Cases and controls were eligible if they were of Caucasian ethnicity, current residents of the study region, and below 80 years of age. Information on known and supposed risk factors was collected for all participants via in-person interviews. The response rate for cases was 88% and for controls 67%. DNA samples were available for 1,021 cases (89%) and 1,015 controls (88%). Characteristics of the study population regarding potential breast cancer risk factors include age at diagnosis (\50, C50 years), menopausal status (premenopausal, postmenopausal), family history of at least one firstdegree relative with breast or ovarian cancer (yes, no), use of oral contraceptives (never,[0 to\5, 5 to\10, C10 years), use of hormone therapy (never,[0 to\10, C10 years), body mass index (\20, 20 to \25, 25 to \30, C30 kg/m 2 ), and smoking status (never, former, current) ( Table 1) .
Information on clinical and histo-pathological tumor characteristics was available for 1,011 (99%) breast cancer cases. The dataset included estrogen receptor status (positive, negative), progesterone receptor status (positive, negative), grading (G1, G2, G3), tumor size (T1, T2, T3, T4), histology (ductal, lobular, ductolobular), and nodal status (N0, CN1) ( Table 1) .
The GENICA study was approved by the Ethic's Committee of the University of Bonn. All study participants gave written informed consent.
Isolation of DNA and genotyping
Genomic DNA was extracted from heparinized blood samples (Puregene TM , Gentra Systems, Inc., Mineapolis, MN, USA) as previously described [27] . A total of 23 polymorphisms located in SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 and eight polymorphisms in PXR were selected on the basis of a known or a potential functional consequence and an allele frequency of at least 2% in Caucasians. 191) , and PXR_11156_A[C (rs3814057) were subjected to genotyping of all 2,036 DNA samples which are available from the GENICA collection. Genotyping was performed by matrixassisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) as described previously [27, 28] . A Sequenom Compact MALDI-TOF MS was used for data acquisitions from the SpectroCHIP. Genotyping calls were made with MASSARRAY RT software v 3.0.0.4 (Sequenom, San Diego, CA, USA). For quality control, repeated analyses were performed for 20% randomly selected samples. Primers were synthesised by Metabion International AG, Martinsried, Germany, sequences are available on request.
Statistical analyses SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1, and PXR genotype frequencies were tested for Hardy-Weinberg equilibrium. Associations between genetic variables and breast cancer risk were analyzed by conditional logistic regression adjusted for six potential epidemiological breast , and PXR were estimated using Haploview 4.1 [29] . All other statistical analyses were done using SAS v 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Results
We analyzed six polymorphisms located in SLCO1A2, six polymorphisms located in SLCO1B1, three polymorphisms located in SLCO1B3, eight polymorphisms located in SLCO2B1, and eight polymorphisms located in PXR using MALDI-TOF MS. Call rates were [98% and repeated analyses of 20% of randomly selected samples showed 100% concordance. Genotype frequencies of cases and controls met Hardy-Weinberg equilibrium. Statistical analysis revealed that none of these polymorphisms in association with breast cancer risk in general (Table 2 ) or in subgroup analyses with respect to menopausal status, family history of breast cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking (data not shown). Moreover, none of the 31 polymorphisms showed an association with histo-pathological characteristics of breast tumors considering estrogen receptor, progesterone receptor and HER2 status, grading, tumor size, histology as well as node status (data not shown). Furthermore, haplotype analyses revealed no association between SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1, and PXR haplotypes and breast cancer risks (data not shown).
Discussion
To the best of our knowledge, this is the first study on a potential role of SLCO and PXR polymorphisms in breast cancer risk and/or histo-pathological tumor characteristics. We challenged this question due to known biological roles of OATP2 and PXR in breast cancer as well as known pharmacokinetic effects of OATP1B1 variants [5, 6, [15] [16] [17] . Yet, none of the investigated polymorphisms in SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 and none of the investigated PXR polymorphisms were associated with over all breast cancer risk or any of the subgroup risks addressed by menopausal status, family history of breast cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking. With respect to breast tumor characteristics, i.e., estrogen receptor, progesterone receptor and HER2 status, grading, tumor size, histology, and nodal status also no association has been observed. Our study had an 80% power to detect a minimum OR of 1.4 for the 31 polymorphisms (a = 0.05, two-sided test). Our finding of a lack of breast cancer risk association with SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 as well as PXR polymorphisms is of relevance because transporters and their translational modifiers are key players in the uptake and elimination of endogenous substrates, xenobiotics and drugs. While we limited our analyses to polymorphism of a small number of transporters of organic anions (OATPs) it is of note that at least 5% ([2,000) of all genes are transporter related consistent with their biological significance and their role in cell homeostasis [9] . We therefore cannot exclude that breast cancer susceptibility and/or tumor characteristics may be conferred by variants in other solute carriers (e.g., other OATPs, OATs, OCTs) and/or in ATP-binding cassette membrane transporters (e.g., ABCB and ABCC) or variants in other related gene [10, 20] , as is has been shown for sodium bicarbonate cotransporter SLC4A7 [24] .
